Yeztugo, approved by the FDA, was highly effective in two randomized trials. It costs $28,218 per year, and people have to be ...

The Food and Drug Administration approved the preventative use of lenacapavir, made by Gilead Sciences, on Wednesday. Experts ...

Researchers from MIT and Scripps have unveiled a promising new HIV vaccine approach that generates a powerful immune response ...

Colombian billionaire Jaime Gilinski Bacal is open to selling his majority stake in British lender Metro Bank and has ...

The Trump administration says the funding does not align with its policies, and says it may appeal the ruling.

Researchers have provided more evidence that mpox virus can be passed from a pregnant mother to her child. There remain ...

The Wistar Institute has launched its HIV Cure and Viral Diseases Center with new lab space on Market Street and a plan to ...

The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that ...

Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.

The approval could slow new infections and move the world closer to eliminating HIV. But huge obstacles remain.

The breakthrough double injection won’t be cheap in the US, although scientists argue it could (and should) be.

The dapivirine ring was originally approved in July 2020 to reduce the risk for HIV-1 infection in women 18 years and older ...